{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"117-460-444-307-899","frontPageModel":{"patentViewModel":{"ref":{"entityRefType":"PATENT","entityRefId":"117-460-444-307-899"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":10753,"type":"PATENT","title":"Paris-Sud University: Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":2442,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8235,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately:\"univ* paris sud\"; \"univ* paris 11\"; \"univ* paris xi\"; \"Paris-Sud Univ*\".
Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 2075
Search Applicants and Owners separately:\"univ* paris sud\"; \"univ* paris 11\"; \"univ* paris xi\"; \"Paris-Sud Univ*\".
Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 2075
- Gag protein having the sequence SEQ ID NO: 5,
- Pro protein having the sequence SEQ ID NO: 6,
- Pol protein having the sequence SEQ ID NO: 7,
- Env protein having the sequence SEQ ID NO: 8, and
- the accessory Rec protein having the sequence SEQ ID NO: 9."],"number":6,"annotation":false,"title":false,"claim":true},{"lines":["Nucleic acid molecule according to anyone of claims 1 to 3, or protein according to claims 5 or 6, as a medicament, preferably as an immunogen or as a vaccine."],"number":7,"annotation":false,"title":false,"claim":true},{"lines":["Nucleic acid molecule according to anyone of claims 1 to 3, or protein according to claims 5 or 6, for their use for the prevention or the treatment of cancer, more preferably for the prevention or the treatment of cancer induced by the activation of the transcription of env gene HERV-K in animal or human."],"number":8,"annotation":false,"title":false,"claim":true},{"lines":["Composition comprising at least one protein encoded by the nucleic acid molecule of the consensus HERV-K(HML2) provirus, named \"Phoenix\" provirus, in association with a pharmaceutically acceptable carrier."],"number":9,"annotation":false,"title":false,"claim":true},{"lines":["Composition according to claim 9, wherein said composition comprises at least one, preferably 2, 3 or all the proteins encoded by the nucleic acid molecule of the consensus HERV-K(HML2) provirus, said proteins being chosen among the group consisting of:
- Gag protein having the sequence SEQ ID NO: 5,
- Pro protein having the sequence SEQ ID NO: 6,
- Pol protein having the sequence SEQ ID NO: 7,
- Env protein having the sequence SEQ ID NO: 8 and
- the accessory Rec protein having the sequence SEQ ID NO: 9 protein having the sequence."],"number":10,"annotation":false,"title":false,"claim":true},{"lines":["Composition according to claim 9 or 10 for their use for the preparation of vaccinal antigens in a composition intended to the prevention or the treatment of cancer."],"number":11,"annotation":false,"title":false,"claim":true},{"lines":["Pharmaceutical composition comprising
- at least one, preferably at least 2, 3 or all the proteins encoded by the nucleic sequence of the consensus HERV-K(HML2) provirus having the sequence SEQ ID NO: 4,
- andin association with a pharmaceutically acceptable vehicle."],"number":12,"annotation":false,"title":false,"claim":true},{"lines":["Pharmaceutical composition according to claim 12, wherein said protein expressed by an endogenous retrovirus is an env gene HERV encoded protein, preferably immunosuppressive, mutated or not, or fragment thereof comprising the immunosuppressive domain, mutated or not, of said env gene HERV encoded protein."],"number":13,"annotation":false,"title":false,"claim":true},{"lines":["Pharmaceutical composition according to claim 12 or 13, wherein said endogenous retrovirus is HERV-K, preferably an HERV-K sub-type expressing an env protein characterized in that the open reading frame encoding the env HERV-K protein encodes a Np9 protein, preferably HERV-K sub-type selected from the group consisting of the HERV-K sub-type HERV-K101, HERV-K102, HERV-K107 and HERV-K(II)."],"number":14,"annotation":false,"title":false,"claim":true},{"lines":["Pharmaceutical composition according to anyone of claims 12 to 14, wherein said protein expressed by an endogenous retrovirus is a Np9 protein having an amino acid sequence selected from the group consisting of:• an env gene endogenous retrovirus encoded immunosuppressive protein, mutated or not, or a fragment thereof comprising an immunosuppressive domain, mutated or not, of said env gene endogenous retrovirus encoded protein, and/or• a ligand, such as antibodies, said ligand being capable of specifically binding an env gene endogenous retrovirus encoded immunosuppressive protein, mutated or not, or a fragment thereof comprising an immunosuppressive domain, mutated or not, of said env gene endogenous retrovirus encoded protein, and/or• a double stranded RNA, siRNA, shRNA, miRNA or an antisense nucleic acid targeting nucleic acid sequences of the endogenous retrovirus and/or of a protein expressed by said endogenous retrovirus,
a) the amino acid sequence of HERV-K sub-type Np9 protein as depicted in Genbank (GenPept) under the Accession Number, P61580, P61581, P61582 and P61583; and
b) an amino acid sequence having at least 75 % identity with an amino acid sequence of a) and having an immunosuppressive activity."],"number":15,"annotation":false,"title":false,"claim":true},{"lines":["Pharmaceutical composition comprising
- an inhibitor of the expression and/or of the activity of at least one, preferably at least 2, 3 or all the proteins encoded by the nucleic sequence of the consensus HERV-K(HML2) provirus having the sequence SEQ ID NO: 4,
- andin association with a pharmaceutically acceptable vehicle."],"number":16,"annotation":false,"title":false,"claim":true}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}• an env gene endogenous retrovirus encoded immunosuppressive protein, mutated or not, or a fragment thereof comprising an immunosuppressive domain, mutated or not, of said env gene endogenous retrovirus encoded protein, and/or• a ligand, such as antibodies, said ligand being capable of specifically binding an env gene endogenous retrovirus encoded immunosuppressive protein, mutated or not, or a fragment thereof comprising an immunosuppressive domain, mutated or not, of said env gene endogenous retrovirus encoded protein, and/or• a double stranded RNA, siRNA, shRNA, miRNA or an antisense nucleic acid targeting nucleic acid sequences of the endogenous retrovirus and/or of a protein expressed by said endogenous retrovirus,